Genetic Signatures (ASX: GSS) is an Australian-listed company in the Healthcare sector with a market capitalisation of $14.8M and the 1384th-largest security on the ASX by market capitalisation. The GSS share price is $0.065, down 1.52% today and down 83.08% over the past 12 months. Shares have traded between $0.064 and $0.43 over the past 52 weeks. In its most recent reported period (ending 31 Dec 2025), Genetic Signatures reported revenue of $8.7M and a net loss of $6.4M.
About Genetic Signatures Limited
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
